Statement of Identity section
Niacin Dietary Supplement Extended Release Capsules 500 mg
Niacin Dietary Supplement Extended Release Capsules 500 mg
Do not use this product if you have a known sensitivity or allergy to niacin. Use only under the advice and supervision of a physician if you:have heart disease, abnormal chest pain (angina)or recently suffered a heart attack; are taking high blood pressure or cholestrol lowering drugs(because of possible drug interactions); have any of the following conditions: gallbladder disease, gout, arterial bleeding, diabetes, imparied liver function, peptic ulcer, or are a pregnant or lactating woman.
Keep out of Reach of children. If you are pregnant or nursing a baby, seek the advice of a health professinoal before using this product
DIETARY SUPPLEMENT
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 311959 | niacin 500 MG Extended Release Oral Capsule | PSN | 1 |
| 311959 | niacin 500 MG Extended Release Oral Capsule | SCD | 1 |
| 311959 | nicotinic acid 500 MG Extended Release Oral Capsule | SY | 1 |
| 311959 | vit-B3 500 MG Extended Release Oral Capsule | SY | 1 |
| 311959 | vitamin B3 500 MG Extended Release Oral Capsule | SY | 1 |
| Class | Version | Type | Effective |
|---|---|---|---|
| NIACIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 594e2c86-3079-4e6e-96c9-48f7a8afc78d | Product name | 1 | 20230718 |
| e2dae634-14ed-febf-08ee-93196433b5b7 | Product name | 9 | 20190614 |
| 0a5e5249-329b-0cff-e714-77159f193a87 | Product name | 1 | 20140508 |
| 6b7a6f32-42a6-994d-5ab6-d180e92ee9d8 | Product name | 1 | 20140508 |
| d394f843-7479-dc48-dbd3-232266c5548c | Product name | 1 | 20140508 |
| dc9a5fb6-14e2-1cc8-a567-a781fd1f0212 | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 49483-018-00 | NIACIN | 100000 in 1 CARTON | CAPSULE, EXTENDED RELEASE | 100000 | 1 | |
| 49483-018-01 | NIACIN | 100 in 1 BOTTLE, PLASTIC | CAPSULE, EXTENDED RELEASE | 100 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 49483-018-01 | EA - Each | 49483-018 | d4329b34-4db7-4092-9ff1-5ee0d6565667 | 1 | 2014-05-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| NIACIN | ACTIVE INGREDIENT | 2679MF687A | 1 | |
| NIACIN | ACTIVE MOIETY | 2679MF687A | 1 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| GELATIN | INACTIVE INGREDIENT | 2G86QN327L | 1 | |
| SHELLAC | INACTIVE INGREDIENT | 46N107B71O | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 49483-018 | 49483-018-01, 49483-018-00 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| NIACIN | 2679MF687A | ACTIB |
| SHELLAC | 46N107B71O | IACT |
| GELATIN | 2G86QN327L | IACT |
| SUCROSE | C151H8M554 | IACT |
| TALC | 7SEV7J4R1U | IACT |
| TITANIUM DIOXIDE | 15FIX9V2JP | IACT |
| FD&C BLUE NO. 1 | H3R47K3TBD | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GELATIN | GELATIN | 2G86QN327L | TABLET, ORALLY DISINTEGRATING / ORAL | 120 mg | ||
| GELATIN | GELATIN | 2G86QN327L | POWDER / ORAL | 100 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, EXTENDED RELEASE / ORAL | 5119 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOLUTION / RECTAL | 0.01 %w/v | ||
| TALC | TALC | 7SEV7J4R1U | GRANULE, FOR SUSPENSION / ORAL | 296 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOLUTION / DENTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 18 mg | ||
| GELATIN | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 14 mg | ||
| TALC | TALC | 7SEV7J4R1U | POWDER / TOPICAL | 9235 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | DROPS / ORAL | NA | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, ORALLY DISINTEGRATING / ORAL | 80 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / ORAL | 72 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, LIQUID FILLED / ORAL | 12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| GELATIN | GELATIN | 2G86QN327L | SOLUTION / INTRAVENOUS | 34.8 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | TABLET, FILM COATED / ORAL | 4.4 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | TABLET, DELAYED RELEASE / ORAL | 8 mg | ||
| TALC | TALC | 7SEV7J4R1U | OINTMENT / TOPICAL | 74.6 %w/w | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| GELATIN | GELATIN | 2G86QN327L | TABLET / PERIODONTAL | 3.44 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / SUBLINGUAL | 32.4 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED / ORAL | 91 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CONCENTRATE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, COATED PELLETS / ORAL | 14 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SHELLAC | SHELLAC | 46N107B71O | CAPSULE, COATED PELLETS / ORAL | 29 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET / SUBLINGUAL | 0.03 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | TABLET, COATED / ORAL | 30 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CREAM / TOPICAL | 80 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY / VAGINAL | NA | ||
| SHELLAC | SHELLAC | 46N107B71O | FILM / SUBLINGUAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | TABLET, EXTENDED RELEASE / ORAL | 213.24 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOLUTION / ORAL | 1.13 mg/15ml | ||
| GELATIN | GELATIN | 2G86QN327L | CAPSULE, COATED / ORAL | 288 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | ELIXIR / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| GELATIN | GELATIN | 2G86QN327L | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SYRUP / ORAL | 0.05 mg/5ml | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| GELATIN | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 14 mg | ||
| GELATIN | GELATIN | 2G86QN327L | TABLET / SUBLINGUAL | 19 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER, FOR SUSPENSION / ORAL | 297 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED / ORAL | 17 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CONCENTRATE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Niacin | NIACIN | Amneal Pharmaceuticals LLC | 6e604319-e164-4056-ab80-b78b98c519c7 | 2026-08-04 | Warnings, Adverse reactions | Niacin NIACIN |
| Niacin | NIACIN | Golden State Medical Supply, Inc. | 8eff9205-84ac-e69d-e053-2995a90aad4b | 2026-04-15 | Warnings, Adverse reactions | Niacin NIACIN |
| Niacin | NIACIN | AvPAK | dd60fe81-3d54-4a29-9502-601be89c575e | 2026-02-25 | Warnings, Adverse reactions | Niacin NIACIN |
| Niacin | NIACIN | QUAGEN PHARMACEUTICALS LLC | 249e27ac-e1e7-42dc-84f6-cd32fd1d9dee | 2025-12-25 | Warnings, Adverse reactions | Niacin NIACIN |
| Niacin | NIACIN | Redmont Pharmaceuticals, LLC | f51f7e6d-b132-48d8-8bb1-54203472f0d8 | 2025-12-17 | Warnings, Adverse reactions | Niacin NIACIN |
| NIACIN | NIACIN | Chartwell RX, LLC | 568c3a99-b6e8-48b4-bb68-867bbcefa027 | 2025-12-08 | Warnings, Adverse reactions | NIACIN NIACIN |
| Niacin | NIACIN | Lannett Company, LLC | d7b66e13-00ed-48a9-a54a-8e474cc31d54 | 2025-11-10 | Warnings, Adverse reactions | Niacin NIACIN |
| Niacin | NIACIN | Amneal Pharmaceuticals LLC | 7250313b-b2ef-4736-bd25-2f29c2ac0eb9 | 2025-10-03 | Warnings, Adverse reactions | Niacin NIACIN |
| Niacin | NIACIN | Macleods Pharmaceuticals Limited | 52ad4a6a-81cc-4b03-b8b1-3bd9a1d4064e | 2025-01-10 | Warnings, Adverse reactions | Niacin NIACIN |
| NIACIN | NIACIN | Sun Pharmaceutical Industries, Inc. | 8e290f96-e8c6-47fd-863f-1c9480f28d9b | 2023-11-24 | Warnings, Adverse reactions | NIACIN NIACIN |
| NIACIN | NIACIN | Lupin Pharmaceuticals, Inc. | 92b3ec1d-0dc7-4bde-9817-57b1bdf7f0b9 | 2023-10-06 | Warnings, Adverse reactions | NIACIN NIACIN |
| Niacin | NIACIN | Aurobindo Pharma Limited | 43233a21-3f90-4c69-bbeb-f50d5f2d35ae | 2023-02-14 | Warnings, Adverse reactions | Niacin NIACIN |
| Niacor | NIACIN | Avondale Pharmaceuticals, LLC | bf287412-160b-403f-8eb4-57f29a475902 | 2021-12-23 | Warnings, Adverse reactions | NIACIN |
| Niacin | NIACIN | Emerald Therapeutics, LLC | 5fceeb58-e54d-43c1-8abb-33feea69d663 | 2021-04-07 | Warnings, Adverse reactions | Niacin NIACIN |
Adverse event summaries are temporarily unavailable. Other product information remains available.